AACR . Siempre Ha Sido un Congreso en Donde Se Presentan Datos Preclínicos o de Fases I - II . Es Relevante Para Poder Intuir en Qué Momemtum Se Encuentran Dichos Ensayos .

 

AACR 2024 : PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine .

*.- Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patients .

*.- Combination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and median progression-free survival of 10.9 months .